Showing 1011-1020 of 21418 results for "".
- Urinary LIF Predicts Recovery in Acute Interstitial Nephritishttps://reachmd.com/news/urinary-lif-predicts-recovery-in-acute-interstitial-nephritis/2488724/Key Takeaways In biopsy-proven AIN, higher LIF in urine collected at biopsy was associated with kidney recovery at 3 months. In the independent AIN validation cohort, adding urinary LIF increased the reported AUC from 0.88 to 0.97; the likelihood-ratio test yielded P
- Medspa Industry Sees Double-Digit Growth Despite Flat New-Patient Volume: Reporthttps://reachmd.com/news/medspa-industry-sees-double-digit-growth-despite-flat-new-patient-volume-report/2488729/Revenue across medical aesthetics practices increased during the third quarter of 2026, with existing patients and newer clinic locations accounting for much of the growth, according to CorralData's latest State of Aesthetics report. The report, based on operator systems data rather than s
- Closed vs Open Suctioning in ARDS: Early Lung Impedancehttps://reachmd.com/news/closed-vs-open-suctioning-in-ards-early-lung-impedance/2488723/Key Takeaways Among mechanically ventilated adults with ARDS receiving PEEP ≥5 and <10 cmH₂O in a Beijing intensive care unit, closed suctioning was associated with smaller early losses of global lung impedance. The authors reported earlier global impedance recove
- Study Links Lichen Planus to Increased Oral and Genital Cancer Riskhttps://reachmd.com/news/study-links-lichen-planus-to-increased-oral-and-genital-cancer-risk/2488704/A nationwide Danish cohort study found that patients with lichen planus (LP) had an increased risk of oral, genital, and cutaneous cancers, with the strongest associations observed at anatomical sites affected by the inflammatory condition. The findings, published in JAMA Dermatology, sh
- CD4+ TEMRA Cells, Galectin-7 Linked to IPF Riskhttps://reachmd.com/news/cd4-temra-cells-galectin-7-linked-to-ipf-risk/2488706/Key Takeaways Among patients with IPF, peripheral-blood CD4+ TEMRA cells accounted for 1% versus 2% of T cells in controls. Higher genetically predicted relative CD4+ TEMRA abundance was associated with lower IPF risk in both genetic cohorts. Galectin-7 was
- Real-World RELIEVE-PN Data Show Sustained Itch and Skin Pain Improvements With Dupilumabhttps://reachmd.com/news/real-world-relieve-pn-data-show-sustained-itch-and-skin-pain-improvements-with-dupilumab/2488708/Adults with prurigo nodularis (PN) who initiated dupilumab reported reductions in itch, skin pain, and burning or stinging/tingling symptoms as early as 1 month, with improvements maintained through 9 months, according to a real-world analysis presented at the 2026 Fall Clinical Dermatology Confe
- Bleeding Events Infrequent Around Procedures in Remibrutinib CSU Trial Analysishttps://reachmd.com/news/bleeding-events-infrequent-around-procedures-in-remibrutinib-csu-trial-analysis/2488707/A post hoc analysis of the phase 3 REMIX-1 and REMIX-2 trials found that bleeding events were uncommon among patients receiving remibrutinib who underwent surgical or invasive procedures. The findings were presented at the 2026 Fall Clinical Dermatology Conference.1 Remibrutinib
- 2-Year ICONIC-LEAD Data Show Sustained Psoriasis Responses With Oral Icotrokinrahttps://reachmd.com/news/2-year-iconic-lead-data-show-sustained-psoriasis-responses-with-oral-icotrokinra/2488701/Two-year findings from the Phase 3 ICONIC-LEAD trial showed sustained skin clearance and itch improvement with icotrokinra (ICOTYDE; Johnson & Johnson) in adults and adolescents aged 12 years or older with moderate-to-severe plaque psoriasis, according to data presented at the 2026 Fall Clini
- TOGETHER-PsO Biomarker Analysis Examines Ixekizumab and Tirzepatide in Psoriasis With Obesityhttps://reachmd.com/news/together-pso-biomarker-analysis-examines-ixekizumab-and-tirzepatide-in-psoriasis-with-obesity/2488700/A prespecified exploratory analysis of the phase 3b TOGETHER-PsO trial found broader changes in circulating proteins and blood gene expression among adults receiving concomitant ixekizumab (Taltz; Eli Lilly) and tirzepatide (Zepbound; Eli Lilly) than among those receiving ixekizumab alone, accord
- Combined SMAS Fixation Strategy Associated With Improved Deep Plane Facelift Outcomeshttps://reachmd.com/news/combined-smas-fixation-strategy-associated-with-improved-deep-plane-facelift-outcomes/2488693/A combination of oblique facial fixation and horizontal neck fixation was associated with higher patient satisfaction and greater wrinkle severity improvement following deep plane rhytidectomy, according to findings from a retrospective study published in Aesthetic Plastic Surgery. <